41 research outputs found
Recommended from our members
USE OF ELECTRON SHUTTLES TO BIOLOGICALLY ENHANCE ABIOTIC DECHLORINATION
Geometrical and Physical Properties of Circumbinary Discs in Eccentric Stellar Binaries
In a previous work (Pichardo et al. 2005), we studied stable configurations
for circumstellar discs in eccentric binary systems. We searched for "invariant
loops": closed curves (analogous to stable periodic orbits in time-independent
potentials) that change shape with the binary orbital phase, as test particles
in them move under the influence of the binary potential. This approach allows
us to identify stable configurations when pressure forces are unimportant, and
dissipation acts only to prevent gas clouds from colliding with one another. We
now extend this work to study the main geometrical properties of circumbinary
discs. We have studied more than 100 cases with a range in eccentricity 0 .le.
e .le. 0.9, and mass ratio 0.1 .le. q .le. 0.9. Although gas dynamics may
impose further restrictions, our study sets lower stable bounds for the size of
the central hole in a simple and computationally cheap way, with a relation
that depends on the eccentricity and mass ratio of the central binary. We
extend our previous studies and focus on an important component of these
systems: circumbinary discs. The radii for stable orbits that can host gas in
circumbinary discs are sharply constrained as a function of the binary's
eccentricity. The circumbinary disc configurations are almost circular, with
eccentricity e_d < 0.15, but if the mass ratio is unequal the disk is offset
from the center of mass of the system. We compare our results with other
models, and with observations of specific systems like GG Tauri A, UY Aurigae,
HD 98800 B, and Fomalhaut, restricting the plausible parameters for the binary.Comment: 12 pages, 10 figures and 6 tables. MNRAS, accepte
Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours
BACKGROUND: Cancer is the leading cause of death in older dogs and its prevalence is increasing. There is clearly a need to develop more effective anti-cancer drugs in dogs. SG2000 (SJG-136) is a sequence selective DNA minor groove cross-linking agent. Based on its in vitro potency, the spectrum of in vivo and clinical activity against human tumours, and its tolerability in human patients, SG2000 has potential as a novel therapeutic against spontaneously occurring canine malignancies. RESULTS: In vitro cytotoxicity was assessed using SRB and MTT assays, and in vivo activity was assessed using canine tumour xenografts. DNA interstrand cross-linking (ICL) was determined using a modification of the single cell gel electrophoresis (comet) assay. Effects on cell cycle distribution were assessed by flow cytometry and measurement of γ-H2AX by immunofluorescence and immunohistochemistry. SG2000 had a multi-log differential cytotoxic profile against a panel of 12 canine tumour cell lines representing a range of common tumour types in dogs. In the CMeC-1 melanoma cell line, DNA ICLs increased linearly with dose following a 1 h treatment. Peak ICL was achieved within 1 h and no removal was observed over 48 h. A relationship between DNA ICL formation and cytotoxicity was observed across cell lines. The formation of γ-H2AX foci was slow, becoming evident after 4 h and reaching a peak at 24 h. SG2000 exhibited significant anti-tumour activity against two canine melanoma tumour models in vivo. Anti-tumour activity was observed at 0.15 and 0.3 mg/kg given i.v. either once, or weekly x 3. Dose-dependent DNA ICL was observed in tumours (and to a lower level in peripheral blood mononuclear cells) at 2 h and persisted at 24 h. ICL increased following the second and third doses in a repeated dose schedule. At 24 h, dose dependent γ-H2AX foci were more numerous than at 2 h, and greater in tumours than in peripheral blood mononuclear cells. SG2000-induced H2AX phosphorylation measured by immunohistochemistry showed good correspondence, but less sensitivity, than measurement of foci. CONCLUSIONS: SG2000 displayed potent activity in vitro against canine cancer cell lines as a result of the formation and persistence of DNA ICLs. SG2000 also had significant in vivo antitumour activity against canine melanoma xenografts, and the comet and γ-H2AX foci methods were relevant pharmacodynamic assays. The clinical testing of SG2000 against spontaneous canine cancer is warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12917-015-0534-2) contains supplementary material, which is available to authorized users
Effect of Different Stellar Galactic Environments on Planetary Discs I: The Solar Neighbourhood and the Birth Cloud of the Sun
We have computed trajectories, distances and times of closest approaches to
the Sun by stars in the Solar neighbourhood with known position, radial
velocity and proper motions. For this purpose we have used a full potential
model of the Galaxy that reproduces the local z-force, the Oort constants, the
local escape velocity, and the rotation curve of the Galaxy. From our sample we
constructed initial conditions, within observational uncertainties, with a
Monte Carlo scheme for the twelve most suspicious candidates because of their
small tangential motion. We find that the star Gliese 710 will have the closest
approach to the Sun, with a distance of approximately 0.34 pc at 1.36 Myr in
the future. We show that the effect of a flyby with the characteristics of
Gliese 710 on a 100 AU test particle disk representing the Solar system is
negligible. However, since there is a lack of 6D data for a large percentage of
stars in the Solar neighbourhood, closer approaches may exist. We calculate
parameters of passing stars that would cause noticeable effects on the Solar
disk. Regarding the birth cloud of the Sun, we performed experiments to
reproduce roughly the observed orbital parameters such as eccentricities and
inclinations of the Kuiper Belt. It is known now that in Galactic environments,
such as stellar formation regions, the stellar densities of new born stars, are
high enough to produce close encounters within 200 AU. Moreover, in these
Galactic environments, the velocity dispersion is relatively low, typically
approximately 1-3 km s-1.We find that with a velocity dispersion of
approximately 1 km s-1 and an approach distance of about 150 AU, typical of
these regions, we obtain approximately the eccentricities and inclinations seen
in the current Solar system. Simple analytical calculations of stellar
encounters effects on the Oort cloud are presented.Comment: Accepted 2011 August 2 by MNRAS (Monthly Notices of the Royal
Astronomical Society Main Journal). Received 2011 June 27; in original form
2010 June 10 The paper contains 10 figures and 5 table
Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
<p>Abstract</p> <p>Background</p> <p>Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), can reduce transfusions and increase hemoglobin (Hb) levels in patients with chemotherapy-induced anemia (CIA). Recent safety concerns, however, have prompted changes to ESA product information. In the European Union and United States, ESA therapy initiation for CIA is now recommended at a Hb level ≤10 g/dL. The present exploratory analysis examined how ESA initiation at this Hb level may impact patient care.</p> <p>Methods</p> <p>Data from a phase 3 randomized trial were retrospectively reanalyzed. CIA patients with nonmyeloid malignancies were randomized 1:1 to 500 mcg darbepoetin alfa every three weeks (Q3W) or 2.25 mcg/kg darbepoetin alfa weekly (QW) for 15 weeks. A previously published report from this trial showed Q3W dosing was non-inferior to QW dosing for reducing transfusions from week 5 to end-of-the-treatment period (EOTP). In the present analysis, outcomes were reanalyzed by baseline Hb <10 g/dL and ≥10 g/dL. Endpoints included transfusion rates, Hb outcomes, and safety profiles.</p> <p>Results</p> <p>This study reanalyzed 351 and 354 patients who initiated ESA therapy at a baseline Hb of <10 g/dL or ≥10 g/dL, respectively. From week 5 to EOTP, the estimated Kaplan-Meier transfusion incidence (Q3W vs QW) was lower in the ≥10 g/dL baseline-Hb group (14% vs 21%) compared with the <10 g/dL baseline-Hb group (36% vs 41%). By week 5, the ≥10 g/dL baseline-Hb group, but not the <10 g/dL baseline-Hb group, achieved a mean Hb ≥11 g/dL. The Kaplan-Meier estimate of percentage of patients (Q3W vs QW) who achieved Hb ≥11 g/dL from week 1 to EOTP was 90% vs 85% in the ≥10 g/dL baseline-Hb group and 54% vs 57% in the <10 g/dL baseline-Hb group. Both baseline-Hb groups maintained mean Hb levels <12 g/dL and had similar safety profiles, though more patients in the ≥10 g/dL baseline-Hb group reached the threshold Hb of ≥13 g/dL.</p> <p>Conclusion</p> <p>In this exploratory analysis, darbepoetin alfa Q3W and QW raised Hb levels and maintained mean Hb at <12 g/dL in both baseline-Hb groups. The ≥10 g/dL baseline-Hb group had fewer transfusions and faster anemia correction. Additional studies should prospectively evaluate the relationship between Hb levels at ESA initiation and outcomes.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov Identifier NCT00118638.</p
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
BACKGROUND: Cancer patients often develop the potentially debilitating condition of anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents (ESAs) can raise haemoglobin levels and reduce transfusion requirements in anaemic cancer patients receiving chemotherapy. To evaluate recent safety concerns regarding ESAs, we carried out a meta-analysis of controlled ESA oncology trials to examine whether ESA use affects survival, disease progression and risk of venous-thromboembolic events
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
BACKGROUND:
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes.
METHODS:
We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization.
RESULTS:
During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events.
CONCLUSIONS:
Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)